🏛️ Verified NIH Record • Updated 2026-08-07

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (NCT06989112)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Who can join: Review the eligibility criteria below.

Location: Research Site — Tucson, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (252 Sites)

  • Research Site — Tucson, Arizona
  • Research Site — Little Rock, Arkansas
  • Research Site — Duarte, California
  • Research Site — Irvine, California
  • Research Site — La Jolla, California
  • Research Site — Palo Alto, California
  • Research Site — San Francisco, California
  • Research Site — Sylmar, California
  • Research Site — Fort Myers, Florida
  • Research Site — Miami, Florida
  • Research Site — Miami Beach, Florida
  • Research Site — Orlando, Florida
  • Research Site — St. Petersburg, Florida
  • Research Site — Tampa, Florida
  • Research Site — West Palm Beach, Florida
  • Research Site — Augusta, Georgia
  • Research Site — Honolulu, Hawaii
  • Research Site — Arlington Heights, Illinois
  • Research Site — Evanston, Illinois
  • Research Site — Shreveport, Louisiana
  • Research Site — Baltimore, Maryland
  • Research Site — Silver Spring, Maryland
  • Research Site — Boston, Massachusetts
  • Research Site — Worcester, Massachusetts
  • Research Site — Ann Arbor, Michigan

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗